Oral Presentation
Towards personalised medicine in COPD: biological and clinical phenotypes
10:45
Basal membrane biomarkers in stable and exacerbated COPD
D. Schumann(Basel, Switzerland)
COI
1
11:00
Blood biomarker algorithms to guide COPD assessment and risk stratification
B. Masters(Billerica, United States)
COI
2
11:15
IFNL3 polymorphisms are associated with COPD severity and outcomes
D. Stolz(Freiburg, Germany)
COI
3
11:30
Increased expression of Lysosomal-associated membrane protein 1 (LAMP-1) found in small airway epithelium of COPD may have functional consequence and role in autophagy.
M. Eapen(Hobart (TAS), Australia)
COI
4
11:45
Lung core-predominant emphysema is associated with higher symptom burden in COPD: analysis of the COPDGene cohort
M. Han(Ann Arbor, United States)
COI
5
12:00
Sensitisation to Aspergillus fumigatus as a risk factor for bronchiectasis in COPD
S. Everaerts(Leuven, Belgium)
COI
6
12:15
Influence of bronchiectasis in patients hospitalized due to acute exacerbation of COPD.
L. Ramirez Garcia(Madrid, Spain)
COI
7
12:30
Serum Levels of Club-Cell Protein 16 (CC-16), Surfactant Protein D (SPD), soluble Receptor of Glycation End-products (sRAGE), Fibrinogen and C-Reactive Protein (CRP) and FEV1 Decline, Exacerbations and Mortality in SUMMIT
B. Celli Croquer(Boston, United States)
COI
8
. . .
